ClinicalTrials.gg
CompletedNCT05314439Updated Dec 22, 2023

A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension

A Phase 2 interventional study of ION904 and Placebo in Hypertension, sponsored by Ionis Pharmaceuticals, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-22.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 9 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2023.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Enrollment
1,191st of 1,779
48 · median 100
Started
2022
with 94 others
Phase 2
170 of 2,031
21 open now
Registered
1,562nd of 2,031
by date

Among the 2,031 studies in Hypertension with a site in United States, this one is the 1,191st largest by enrollment of the 1,779 interventional ones that give a count, is one of 95 that started in 2022, is one of 170 in phase 2, and was the 1,562nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

267 more — sign in →

All 272 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,031 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of ION904 on plasma angiotensinogen (AGT) in participants with uncontrolled hypertension.

Read the detailed description

This is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study. It will include up to approximately 48 participants with mild to moderate hypertension who have uncontrolled blood pressure (˃ 130 - ≤ 170 millimeters of mercury [mmHg] systolic) and have been on one or more anti-hypertensive medications for at least one month. Following an up to 4-week screening period, eligible participants will receive multiple doses of ION904 during a 13-week treatment period, followed by a 13-week post-treatment follow-up period.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria:

  1. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of (WOCBP), she uses a highly effective method. Aged 18 - 75 inclusive and weighing ≥ 50 kilograms (kg) at the time of
  2. (BMI) ≤ 45.0 kilograms per square meter (kg/m\^2) at screening
  3. History of uncontrolled hypertension (HTN) on one or more antihypertensive medications without changes in antihypertensive regimen within 4 weeks of screening and will be required to maintain this regimen throughout the Treatment Period

General Exclusion Criteria:

  1. History of secondary HTN including, but not limited to any of the following: renovascular HTN (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug induced HTN
  2. Unstable/underlying known cardiovascular disease defined as:

    • Any history of congestive heart failure ( [NYHA] Class III-IV)
    • Any history of previous myocardial infarction, coronary revascularization, unstable or stable angina pectoris ˂ 6 months prior to screening
    • Any hemodynamically unstable atrial or ventricular arrhythmias
    • Significant uncorrected valvular heart disease
    • Any history of stroke or \< 6 months prior to screening
  3. A cardiac valve repair, cardiac device implantation, and/or a hospitalization for heart failure within 3 months of screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    ION904

    Up to 4 monthly doses of ION904 will be administered by subcutaneous (SC) injection.

    Drug: ION904

  • Placebo comparator
    Placebo

    Up to 4 monthly doses of placebo will be administered by SC injection.

    Drug: Placebo

Interventions

  • DrugION904

    ION904 will be administered by SC injection.

  • DrugPlacebo

    Placebo will be administered by SC injection.

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Plasma Angiotensinogen (AGT)

    Time frame: Baseline up to approximately 15 weeks

Secondary outcomes

  1. Change from Baseline in Seated Automated Office Systolic Blood Pressure (SBP)

    Time frame: Baseline up to approximately 15 weeks

  2. Change from Baseline in Seated Automated Office Diastolic Blood Pressure (DBP)

    Time frame: Baseline up to approximately 15 weeks

07

Study locations

8 sites
  • Altasciences - Los Angeles
    Cypress, California 90630, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Clinical Trials Research
    Sacramento, California 95821, United States
  • ALL Medical Research, LLC
    Cooper City, Florida 33024, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Altasciences
    Overland Park, Kansas 66212, United States
  • NY Scientific
    Brooklyn, New York 11235, United States
  • Juno Research, LLC
    Houston, Texas 77040, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jan 2023, 9 months.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 9 months is below that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2022
First posted
Apr 6, 2022
StartActual
Apr 29, 2022
Primary completionActual
Jan 31, 2023
CompletionActual
Feb 15, 2023
Results delay requested
Dec 20, 2023
Last update
Dec 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05314439
Responsible party
Sponsor
First posted
Apr 6, 2022
Start date
Apr 29, 2022
Primary completion
Jan 31, 2023
Completion
Feb 15, 2023
Last update
Dec 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tonlamarsen

Start the discussion